References
- Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 2001;38:S30–3.
- Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005;34:31–5.
- Attman PO, Gustafson A. Lipid and carbohydrate metabolism in uraemia. Eur J Clin Invest 1979;9:285–91.
- Attman PO, Samuelsson O, Alaupovic P. The effect of decreasing renal function on lipoprotein profiles. Nephrol Dial Transplant 2011;26:2572–5.
- Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, Watts GF. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res 2009;50:2524–31.
- Yang CY, Gu ZW, Yang HX, Rohde MF, Gotto AM Jr, Pownall HJ. Structure of bovine milk lipoprotein lipase. J Biol Chem 1989;264:16822–7.
- Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T. A single bolus of a low molecular weight heparin to patients on hemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 2005;20:1172–9.
- Nasstrom B, Stegmayr B, Olivecrona G, Olivecrona T. Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 2004;5:17.
- Mahmood D, Grubbstrom M, Lundberg LD, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis. BMC Nephrol 2010;11:33.
- Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 2003;63: 45–53.
- Blake PG, Daugirdas JT. Physiology of peritoneal dialysis. In: Daugirdas JT, Blake PT, Ing TS, editors. Handbook of dialysis. Philadelphia, USA: Lippincott Williams & Wilkins; 2007. pp. 323–38.
- Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002;40:531–8.
- Nasstrom B, Stegmayr BG, Olivecrona G, Olivecrona T. Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. J Lab Clin Med 2003;142:90–9.
- Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 2012;16:238–43.
- Young SG, Davies BS, Voss CV, Gin P, Weinstein MM, Tontonoz P, Reue K, Bensadoun A, Fong LG, Beigneux AP. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res 2011;52:1869–84.
- Baranowski T, Kralisch S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine fasting-induced adipose factor/angiopoietin-like protein 4 depend on renal function. Horm Metab Res 2011;43:117–20.
- Li C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr Opin Lipidol 2006;17:152–6.
- Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, Gay J, Wilganowski N, Gao C, Du LL, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 2009; 284:13735–45.
- Nilsson SK, Anderson F, Ericsson M, Larsson M, Makoveichuk E, Lookene A, Heeren J, Olivecrona G. Triacylglycerol-rich lipoproteins protect lipoprotein lipase from inactivation by ANGPTL3 and ANGPTL4. Biochim Biophys Acta 2012;1821:1370–8.
- Olivecrona T, Olivecrona G. Lipoprotein and hepatic lipase in lipoprotein metabolism. In: Breckenridge DJ, editor. Lipoproteins in health and disease. London: Arnold; 1999. pp. 223–46.
- Stegmayr B, Olivecrona T, Olivecrona G. Lipoprotein lipase disturbances induced by uremia and hemodialysis. Semin Dial 2009;22:442–4.
- Holmberg B, Stegmayr BG. Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain. Hemodial Int 2009;13:27–31.